While up to 70% of low-grade ESS cases have shown positive EGFR expression [104], suggesting the potential for targeted therapy using monoclonal antibodies against EGFR, other studies have reported much lower expression rates (as low as 11%), with no evidence of EGFR gene amplification. Here, EGFR is linked to endometrioid stromal sarcoma.